Population-Based Mechanistic Prediction of Oral Drug Absorption

The bioavailability of drugs from oral formulations is influenced by many physiological factors including gastrointestinal fluid composition, pH and dynamics, transit and motility, and metabolism and transport, each of which may vary with age, gender, race, food, and disease. Therefore, oral bioavailability, particularly of poorly soluble and/or poorly permeable compounds and those that are extensively metabolized, often exhibits a high degree of inter- and intra-individual variability. While several models and algorithms have been developed to predict bioavailability in an average person, efforts to accommodate intrinsic variability in the component processes are less common. An approach that incorporates such variability for human populations within a mechanistic framework is described together with examples of its application to drug and formulation development.

[1]  Masoud Jamei,et al.  Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.

[2]  D. Thakker,et al.  Rhodamine 123 Requires Carrier-Mediated Influx for Its Activity as a P-Glycoprotein Substrate in Caco-2 Cells , 2003, Pharmaceutical Research.

[3]  A. Serajuddin,et al.  Measurement of surface pH of pharmaceutical solids: a critical evaluation of indicator dye-sorption method and its comparison with slurry pH method. , 2008, Journal of pharmaceutical sciences.

[4]  Lawrence X. Yu,et al.  Compartmental transit and dispersion model analysis of small intestinal transit flow in humans , 1996 .

[5]  J. Kolars,et al.  First-pass metabolism of cyclosporin by the gut , 1991, The Lancet.

[6]  K. Svanes,et al.  Microsphere method in measurement of blood flow to wall layers of small intestine. , 1986, The American journal of physiology.

[7]  P. Watkins,et al.  Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. , 1987, The Journal of clinical investigation.

[8]  J. Dressman,et al.  Solubilization and Wetting Effects of Bile Salts on the Dissolution of Steroids , 1991, Pharmaceutical Research.

[9]  L. Di,et al.  Development and Application of an Automated Solution Stability Assay for Drug Discovery , 2006, Journal of biomolecular screening.

[10]  E. Townley,et al.  Parameters affecting absorption of griseofulvin in a human subject using urinary metabolite excretion data. , 1970, Journal of pharmaceutical sciences.

[11]  J. Comer,et al.  Using measured pKa, LogP and solubility to investigate supersaturation and predict BCS class. , 2008, Current drug metabolism.

[12]  J. Dressman,et al.  Estimation of the Increase in Solubility of Drugs as a Function of Bile Salt Concentration , 2004, Pharmaceutical Research.

[13]  Geert Verreck,et al.  Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. , 2007, International journal of pharmaceutics.

[14]  W. S. Snyder,et al.  Report of the task group on reference man , 1979, Annals of the ICRP.

[15]  W H Streng The Gibbs constant and pH solubility profiles. , 1999, International journal of pharmaceutics.

[16]  A. Ridolfo,et al.  Benoxaprofen, a new anti-inflammatory agent: particle-size effect on dissolution rate and oral absorption in humans. , 1979, Journal of pharmaceutical sciences.

[17]  L. A. Christensen,et al.  pH‐Profile and regional transit times of the normal gut measured by a radiotelemetry device , 1989, Alimentary pharmacology & therapeutics.

[18]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[19]  N. Eddington,et al.  The influence of first pass metabolism on the development and validation of an IVIVC for metoprolol extended release tablets. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[20]  E. Straus,et al.  Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). , 1988, Annals of internal medicine.

[21]  L. Knutson,et al.  A new technique for segmental jejunal perfusion in man. , 1989, The American journal of gastroenterology.

[22]  D. D. Bois,et al.  CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .

[23]  B. Gazzard,et al.  Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea , 1999, Gut.

[24]  Lawrence X. Yu,et al.  Predicting Oral Drug Absorption in Humans , 1999 .

[25]  A. Galetin,et al.  Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism , 2006, Journal of Pharmacology and Experimental Therapeutics.

[26]  Thomas J. Vidmar,et al.  Predicting Drug Absorption: How Nature Made It a Difficult Problem , 2002, Journal of Pharmacology and Experimental Therapeutics.

[27]  Lawrence X. Yu,et al.  Characterization of small intestinal transit time distribution in humans , 1998 .

[28]  G L Amidon,et al.  Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. , 1996, Advanced drug delivery reviews.

[29]  R. Arnold Diagnosis and differential diagnosis of hypergastrinemia , 2007, Wiener klinische Wochenschrift.

[30]  Amin Rostami-Hodjegan,et al.  The effects of portal shunts on intestinal cytochrome P450 3A activity , 2002, Hepatology.

[31]  K. Pang,et al.  Disparity in Intestine Disposition between Formed and Preformed Metabolites and Implications: A Theoretical Study , 2009, Drug Metabolism and Disposition.

[32]  J. Comer,et al.  Equilibrium versus kinetic measurements of aqueous solubility, and the ability of compounds to supersaturate in solution--a validation study. , 2006, Journal of pharmaceutical sciences.

[33]  R. Minchin,et al.  Presystemic elimination of drugs: theoretical considerations for quantifying the relative contribution of gut and liver. , 1982, Journal of pharmaceutical sciences.

[34]  R. J. Hintz,et al.  The effect of particle size distribution on dissolution rate and oral absorption , 1989 .

[35]  N. Hosten,et al.  Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging , 2005, Alimentary pharmacology & therapeutics.

[36]  P. Harriott Mass transfer to particles: Part I. Suspended in agitated tanks , 1962 .

[37]  Matthew D. Troutman,et al.  Novel Experimental Parameters to Quantify the Modulation of Absorptive and Secretory Transport of Compounds by P-Glycoprotein in Cell Culture Models of Intestinal Epithelium , 2003, Pharmaceutical Research.

[38]  Lawrence X. Yu An Integrated Model for Determining Causes of Poor Oral Drug Absorption , 1999, Pharmaceutical Research.

[39]  D. Dunbar,et al.  Characterization of human small intestinal cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[40]  R. Remmel,et al.  First-pass disposition of (-)-6-aminocarbovir in rats: II. Inhibition of intestinal first-pass metabolism. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[41]  Elizabeth M. Topp,et al.  Transport processes in pharmaceutical systems , 1999 .

[42]  P. Pentikäinen,et al.  Effect of particle size on the bioavailability of digoxin , 1975, European Journal of Clinical Pharmacology.

[43]  H. Lennernäs,et al.  Regional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man , 1995, Pharmaceutical Research.

[44]  R. Yeates,et al.  Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole , 2004, European Journal of Clinical Pharmacology.

[45]  T. Mano,et al.  Solubility and dissolution profile assessment in drug discovery. , 2007, Drug metabolism and pharmacokinetics.

[46]  D. Greenblatt,et al.  Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole , 1999, Clinical pharmacology and therapeutics.

[47]  A. Glomme,et al.  Predicting the Intestinal Solubility of Poorly Soluble Drugs , 2007 .

[48]  Gordon L. Amidon,et al.  Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.

[49]  G L Amidon,et al.  A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.

[50]  D. Shen,et al.  First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.

[51]  J. Gorski,et al.  The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin , 1998, Clinical pharmacology and therapeutics.

[52]  Gerd Folkers,et al.  Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies , 2006 .

[53]  M. Jamei,et al.  Prediction of the in vivo behaviour of modified release formulations of metoprolol from in vitro dissolution profiles using the ADAM model (Simcyp V8) , 2008 .

[54]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[55]  N. Chalasani,et al.  Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts , 2001, Hepatology.

[56]  Emma L. McConnell,et al.  Meal-Induced Acceleration of Tablet Transit Through the Human Small Intestine , 2009, Pharmaceutical Research.

[57]  Abdul W Basit,et al.  The gastrointestinal microbiota as a site for the biotransformation of drugs. , 2008, International journal of pharmaceutics.

[58]  S. Badawy,et al.  Microenvironmental pH modulation in solid dosage forms. , 2007, Journal of pharmaceutical sciences.

[59]  Hassan Almoazen,et al.  Investigation of Solubility and Dissolution of a Free Base and Two Different Salt Forms as a Function of pH , 2005, Pharmaceutical Research.

[60]  S. Davis,et al.  Alimentary tract andpancreas Transit ofpharmaceutical dosage forms through the , 1986 .

[61]  J. Herron,et al.  Rapid throughput screening of apparent KSP values for weakly basic drugs using 96-well format. , 2008, Journal of pharmaceutical sciences.

[62]  Alex Avdeef,et al.  Absorption and Drug Development: Solubility, Permeability, and Charge State , 2003 .

[63]  R. Wolen,et al.  The effect of crystal size on the bioavailability of benoxaprofen: studies utilizing deuterium labeled drug. , 1979, Biomedical mass spectrometry.

[64]  G. Amidon,et al.  A Residence‐Time Distribution Analysis of the Hydrodynamics within the Intestine in Man during a Regional Single‐pass Perfusion with Loc‐I‐Gut: In‐vivo Permeability Estimation , 1997, The Journal of pharmacy and pharmacology.

[65]  Erich Brunner,et al.  Reaktionsgeschwindigkeit in heterogenen Systemen , 1904 .

[66]  Mark Feldman,et al.  Fasting gastric pH and its relationship to true hypochlorhydria in humans , 1991, Digestive Diseases and Sciences.

[67]  J. Dressman,et al.  Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update , 2008, Pharmaceutical Research.

[68]  J. Dressman,et al.  Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine , 2004, The Journal of pharmacy and pharmacology.

[69]  A. Avdeef Solubility of sparingly-soluble ionizable drugs. , 2007, Advanced drug delivery reviews.

[70]  A. Noyes,et al.  The rate of solution of solid substances in their own solutions , 1897 .

[71]  C. Olsson,et al.  The control of gut motility. , 2001, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[72]  M. Kansy,et al.  Absorption-excipient-pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[73]  J. Dressman,et al.  Estimating drug solubility in the gastrointestinal tract. , 2007, Advanced drug delivery reviews.

[74]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[75]  Hans Lennernäs,et al.  The Effects of Food on the Dissolution of Poorly Soluble Drugs in Human and in Model Small Intestinal Fluids , 2005, Pharmaceutical Research.

[76]  A. Basit,et al.  Gut instincts: explorations in intestinal physiology and drug delivery. , 2008, International journal of pharmaceutics.

[77]  L. Benet,et al.  Tacrolimus oral bioavailability doubles with coadministration of ketoconazole , 1997, Clinical pharmacology and therapeutics.

[78]  Kairui Feng,et al.  The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.

[79]  Stephen D. Clark,et al.  Introductory Statistics—A Modelling Approach , 1995 .

[80]  Lutz Trahms,et al.  Magnetic Marker Monitoring: An application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked solid dosage forms. , 2005, Advanced drug delivery reviews.

[81]  A. Brogna,et al.  Influence of aging on gastrointestinal transit time. An ultrasonographic and radiologic study. , 1999, Investigative radiology.

[82]  M. Jamei,et al.  A Novel Physiologically-Based Mechanistic ModelPredicting Oral Drug Absorption: The Advanced Dissolution, Absorption, and Metabolism (ADAM) Model , 2007 .

[83]  D. L. Madsen,et al.  Effects of gender, age, and body mass index on gastrointestinal transit times , 1992, Digestive Diseases and Sciences.

[84]  W. Nernst,et al.  Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen , 1904 .

[85]  J. Dressman,et al.  Upper Gastrointestinal pH in Seventy-Nine Healthy, Elderly, North American Men and Women , 1993, Pharmaceutical Research.

[86]  H. Paul,et al.  Laboratory studies with nitrofurantoin. Relationship between crystal size, urinary excretion in the rat and man, and emesis in dogs. , 1967, Journal of pharmaceutical sciences.

[87]  Abu T M Serajuddin,et al.  Salt formation to improve drug solubility. , 2007, Advanced drug delivery reviews.

[88]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[89]  S. Shi,et al.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics , 2008, European Journal of Clinical Pharmacology.

[90]  Hans Lennernäs,et al.  Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. , 2009, Molecular pharmaceutics.

[91]  S. Chong,et al.  P-gp Inhibition Potential in Cell-Based Models: Which “Calculation” Method is the Most Accurate? , 2008, The AAPS Journal.

[92]  J. Lin,et al.  Pharmacokinetic and Pharmacodynamic Properties of Histamine H2-Receptor Antagonists , 1991, Clinical pharmacokinetics.

[93]  J. Graff,et al.  Gastrointestinal mean transit times in young and middle-aged healthy subjects. , 2001, Clinical physiology.

[94]  L. Benet,et al.  Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction , 1992, Clinical pharmacology and therapeutics.

[95]  G L Amidon,et al.  Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[96]  M. Paine,et al.  P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine , 2003, Pharmaceutical Research.

[97]  R. Minchin,et al.  Metabolism of drugs and other xenobiotics in the gut lumen and wall. , 1990, Pharmacology & therapeutics.

[98]  N. Kaniwa,et al.  Assessment of gastric acidity of Japanese subjects over the last 15 years. , 2001, Biological & pharmaceutical bulletin.

[99]  C. Beglinger,et al.  Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation , 1996, British journal of pharmacology.

[100]  G. Amidon,et al.  Particle diffusional layer thickness in a USP dissolution apparatus II: a combined function of particle size and paddle speed. , 2008, Journal of pharmaceutical sciences.

[101]  Kiyohiko Sugano,et al.  Theoretical dissolution model of poly-disperse drug particles in biorelevant media. , 2008, Journal of pharmaceutical sciences.

[102]  L Zhang,et al.  A regulatory viewpoint on transporter-based drug interactions. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[103]  M. Manns,et al.  UDP-glucuronosyltransferase activity in human liver and colon. , 1999, Gastroenterology.

[104]  M. Jamei,et al.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.

[105]  M. Fromm,et al.  Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin , 1996, Hepatology.

[106]  D. Flanagan,et al.  General solution for diffusion-controlled dissolution of spherical particles. 2. Evaluation of experimental data. , 2002, Journal of pharmaceutical sciences.

[107]  P. Cohen,et al.  Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS). , 1988, Annals of internal medicine.

[108]  G. Tucker,et al.  Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[109]  A. Basit,et al.  Interplay Between Intestinal pH, Transit Time and Feed Status on the In Vivo Performance of pH Responsive Ileo-Colonic Release Systems , 2008, Pharmaceutical Research.

[110]  J. Crison,et al.  Drug dissolution into micellar solutions: development of a convective diffusion model and comparison to the film equilibrium model with application to surfactant-facilitated dissolution of carbamazepine. , 1996, Journal of pharmaceutical sciences.

[111]  Kevin C. Johnson,et al.  Dissolution and Absorption Modeling: Model Expansion to Simulate the Effects of Precipitation, Water Absorption, Longitudinally Changing Intestinal Permeability, and Controlled Release on Drug Absorption , 2003, Drug development and industrial pharmacy.

[112]  J. Lin,et al.  Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. , 1997, Biochemical pharmacology.

[113]  M Rowland,et al.  Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.

[114]  J. Dressman,et al.  Upper Gastrointestinal (GI) pH in Young, Healthy Men and Women , 1990, Pharmaceutical Research.

[115]  In vivo assessment of intestinal drug metabolism. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[116]  I. Gardner,et al.  Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[117]  Amin Rostami-Hodjegan,et al.  Cytochrome P450 3A expression and activity in the human small intestine , 2004, Clinical pharmacology and therapeutics.

[118]  M. Fromm,et al.  Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique , 2001, Clinical pharmacology and therapeutics.

[119]  M. J. Story,et al.  Reduced bioavailability of atenolol in man : the role of bile acids , 1993 .

[120]  R. Tukey,et al.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease. , 2000, Annual review of pharmacology and toxicology.

[121]  J. DeSesso,et al.  Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[122]  Oliver Burk,et al.  Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens , 2004, Clinical pharmacology and therapeutics.

[123]  J. Valentin Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.

[124]  J. Hardcastle,et al.  Measurement of gastrointestinal pH profiles in normal ambulant human subjects. , 1988, Gut.

[125]  M. Wilson,et al.  Regulation of intestinal blood flow. , 2000, The Journal of surgical research.

[126]  P. Hellström,et al.  Nationwide standardisation and evaluation of scintigraphic gastric emptying: reference values and comparisons between subgroups in a multicentre trial , 2000, European Journal of Nuclear Medicine.

[127]  D. D. Bois,et al.  A height-weight formula to estimate the surface area of man , 1916 .

[128]  D. Flanagan,et al.  General solution for diffusion-controlled dissolution of spherical particles. 1. Theory. , 1999, Journal of pharmaceutical sciences.

[129]  J. Dressman,et al.  Comparison of Canine and Human Gastrointestinal Physiology , 1986, Pharmaceutical Research.

[130]  Mary F Paine,et al.  THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.

[131]  M. Manns,et al.  Polymorphic Gene Regulation and Interindividual Variation of UDP-glucuronosyltransferase Activity in Human Small Intestine* , 2000, The Journal of Biological Chemistry.

[132]  H Lennernäs,et al.  Intestinal permeability and its relevance for absorption and elimination , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[133]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[134]  J. Kolars,et al.  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.